# Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V

> **NCT00097396** · PHASE1 · COMPLETED · sponsor: **DynPort Vaccine Company LLC, A GDIT Company** · enrollment: 40 (—)

## Conditions studied

- Pneumonic Plague
- Preventive Therapy

## Interventions

- **BIOLOGICAL:** rF1V vaccine

## Key facts

- **NCT ID:** NCT00097396
- **Lead sponsor:** DynPort Vaccine Company LLC, A GDIT Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11
- **Primary completion:** 2006-07
- **Final completion:** 2006-09
- **Target enrollment:** 40 (—)
- **Last updated:** 2011-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00097396

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00097396, "Safety, Tolerability & Immunogenicity of the Recombinant Plague Vaccine rF1V". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00097396. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*